--- title: "U.S. stock market midday update: GRML down 12.78% on increased volume, no negative news but funds are fleeing?" type: "News" locale: "en" url: "https://longbridge.com/en/news/296809644.md" description: "Greenland Mines fell 12.78%; Moderna fell 4.21%, with a transaction volume of USD 2.433 billion; AbbVie fell 0.33%, with a transaction volume of USD 240 million; Argenx fell 2.81%, with a transaction volume of USD 198 million; Amgen rose 0.42%, with a market value of USD 238.5 billion" datetime: "2026-08-24T15:52:54.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296809644.md) - [en](https://longbridge.com/en/news/296809644.md) - [zh-HK](https://longbridge.com/zh-HK/news/296809644.md) generator: "portal-rs" --- # U.S. stock market midday update: GRML down 12.78% on increased volume, no negative news but funds are fleeing? **U.S. Stock Market Midday Update** Greenland Mines, down 12.78%, with increased trading volume and no significant news recently. The trading is active, with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks Ranked High in Industry Trading Volume** Moderna down 4.21%. Based on recent news, 1. On August 21, Moderna's mRNA cancer vaccine developed in collaboration with Merck achieved positive results in Phase III clinical trials for melanoma, causing the stock price to surge by 177%. However, subsequent profit-taking led to a 24% decline in the stock price. Source: Barron's 2. On August 22, analysts pointed out that Moderna's personalized mRNA cancer vaccine faces high manufacturing and supply chain costs, raising doubts about its long-term commercialization prospects. Source: The Wall Street Journal 3. On August 24, Barclays raised Moderna's target price, optimistic about the potential of its melanoma vaccine, but the stock price still fell over 7%. Source: Zhitong Finance. The biotechnology sector has performed strongly recently, with noticeable capital inflows. AbbVie down 0.33%, with a trading volume of $240 million. Based on recent key news: 1. On August 24, AbbVie rose over 1% in pre-market trading, reaching an all-time high. Fifth Third Bancorp reduced its holdings in AbbVie by 2.1% in Q2, retaining 2.15 million shares valued at $541.38 million. Analysts maintain a "Moderate Buy" rating, with an average target price of $275.95. Positive lung cancer data and updates on beauty product pipelines have positively impacted the stock price. 2. On August 21, Piper Sandler maintained an "Overweight" rating for AbbVie. Analysts are optimistic about AbbVie's future performance, believing that its innovations in lung cancer treatment will drive the stock price up. 3. On August 21, AbbVie presented the latest data on ABBV-706 at the World Lung Cancer Conference. The study showed that the drug has significant efficacy in treating small cell lung cancer, further boosting market confidence in AbbVie. Innovations in lung cancer treatment are driving the stock price up. Argenx down 2.81%. Based on recent news, 1. On August 24, Deutsche Bank downgraded Argenx's rating from Buy to Hold, believing that the recent positive results of Vyvgart have been fully reflected in the market. Deutsche Bank raised the target price from €900 to €925 but believes that the current stock price has fully reflected the expected sales growth, leading to a decline in the stock price. 2. On August 24, MarketBeat reported that Argenx was not included in the list of five stocks recommended by top analysts. Although Argenx currently has a moderate Buy rating among analysts, top analysts believe there are better investment options, which undermines market confidence On August 21, Simply Wall St released an analysis stating that while Argenx's long-term prospects are promising, it did not take into account the latest price-sensitive company announcements or qualitative materials, leading investors to adopt a cautious attitude towards the stock's performance in the short term. The biotechnology sector has been quite volatile recently, and investors need to be cautious. **Stocks with High Market Capitalization in the Industry** Amgen rose by 0.42%. Based on recent key news: 1. On August 21, Piper Sandler raised Amgen's target price from $427 to $457, maintaining an "Overweight" rating. Several institutions have raised their target prices, with BMO setting a target price of $450 and Argus raising its target price from $375 to $460. Several institutional investors increased their holdings in Amgen in the second quarter, including Bridgewater Advisors increasing by 114.5% and Simplicity Wealth increasing by 122.5%. 2. On August 21, the U.S. Federal Trade Commission (FTC) conducted an antitrust review of Amgen's patent application acquisition deal, which may affect the company's future strategy. 3. On August 21, Amgen reached a historical high in its stock price during trading, rising over 1%, currently reported at $435.26. The company's previously announced second-quarter earnings per share were $6.29, exceeding expectations, with revenue growing by 9.5% year-on-year. The overall industry performance is good, with significant capital inflows ### Related Stocks - [GRML.US](https://longbridge.com/en/quote/GRML.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md) - [ARGX.US](https://longbridge.com/en/quote/ARGX.US.md) - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) ## Related News & Research - [Greenland Mines announces 1-for-50 reverse stock split effective Aug. 24](https://longbridge.com/en/news/296498837.md) - [Greenland Mines Provides Corporate and Operational Update; Announces 1-for-50 Reverse Stock Split | GRML Stock News](https://longbridge.com/en/news/296499736.md) - [Greenland Mines (NASDAQ: GRML) Featured in American News Group Commentary on Western Critical Minerals Supply Chain](https://longbridge.com/en/news/296381337.md) - [Greenland Mines (NASDAQ: GRML) Completes Skaergaard Bathymetric Survey, Advances 2026 Drill Program](https://longbridge.com/en/news/296129505.md) - [Greenland Mines Makes Strategic Investment In Anortech](https://longbridge.com/en/news/289923197.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**